Premium
RQ‐PCR based WT1 expression in comparison to BCR‐ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib‐treated chronic myeloid leukaemia
Author(s) -
Schnittger Susanne,
Bacher Ulrike,
Kern Wolfgang,
Tschulik Claudia,
Weiss Tamara,
Haferlach Claudia,
Haferlach Torsten
Publication year - 2009
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2009.07812.x
Subject(s) - imatinib , chronic myeloid leukaemia , breakpoint cluster region , somatic evolution in cancer , cancer research , cohort , oncology , myeloid leukemia , medicine , chromosomal translocation , biology , gene , cancer , genetics , receptor
Summary A retrospective comparison of WT1 and BCR‐ABL1 expression was performed in 40 imatinib‐treated chronic myeloid leukaemia patients. The overall correlation of WT1 and BCR‐ABL1 was low. In two patients WT1 expression was increasing despite very low BCR‐ABL1 levels. As both revealed Ph‐negative aberrant clones, a second independent cohort of 20 cases, all with Ph‐negative clonal evolution, was analysed. High WT1 expression (5·0–177·0%) was detected in a case with +11 and in four of eight cases with +8, but not in cases with del(20q) or −Y. Thus, increasing WT1 levels in molecular responders may indicate Ph‐negative clonal cytogenetic evolution during imatinib treatment.